福萊德瑞克運動失調症（FA）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 德國市場預計將從 2025 年的約 4,500 萬美元成長到 2035 年的約 1.35 億美元（年複合成長率約 11-12%）。
• 目前的療法仍有許多未滿足的需求，而新的疾病修正治療和基因標靶治療的出現正在推動成長。

福萊德瑞克運動失調症（FA）概述

福萊德瑞克運動失調症是一種罕見的體染色體隱性遺傳性神經退化性疾病。最常見的原因是FXN基因內含子1中GAA三核苷酸重複序列的純合擴增，導致frtaxin蛋白表現降低。此病通常在兒童或青春期發病，但少數患者表現為25歲以後發病的晚期髮型。

Frataxin 缺乏會導致粒線體鐵硫叢集酶活性降低、粒線體內鐵累積、氧化壓力和細胞內能量產生受損，最終導致進行神經退化和心肌病。

臨床上，患者會出現進行進行性共濟失調、構音障礙、感覺神經病變、深部肌腱反射消失、脊椎和肥厚型心肌病。其他系統性症狀，例如糖尿病，也可能出現，但認知功能相對保留。大多數病例是由GAA重複序列擴增引起的，但FXN基因的點突變也可導致複合雜合子患病。

從流行病學角度來看，FRDA 在歐洲血統的人群中更為常見，但在世界各地的所有種族群體中都有發現。

主要亮點

• FRDA 是一種罕見的進行性神經肌肉疾病，會造成嚴重的神經系統和心臟負擔。
• 預計美國患有該疾病的人數將從 2025 年的約 8,600 人增加到 2035 年的約 9,300 人（年複合成長率約為 0.7%）。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興療法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• PTC Therapeutics
• Design Therapeutics, Inc.
• Larimar Therapeutics, Inc.
• Biogen
• Lexeo Therapeutics
• Solid Biosciences Inc.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前療法
  • 重點
  • 診斷和治療過程/演算法
  • 主要療法概述及KOL洞察
• 新興療法
  • 重點
  • 值得關注的後期新療法—概述、市場上市預期和KOL洞察
  • 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求以及透過新興療法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Friedreich Ataxia (FA) Market Outlook

Thelansis's "Friedreich Ataxia (FA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Friedreich Ataxia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Friedreich Ataxia (FA) Overview

Friedreich ataxia is a rare autosomal recessive neurodegenerative disorder most commonly caused by homozygous GAA trinucleotide repeat expansions in intron 1 of the FXN gene, which reduce frataxin expression. Typical onset is in childhood or adolescence, although a minority of patients present with late-onset disease after age 25.

Frataxin deficiency leads to impaired mitochondrial iron-sulfur cluster enzyme activity, mitochondrial iron accumulation, oxidative stress, and disrupted cellular energy production, ultimately driving progressive neurodegeneration and cardiomyopathy.

Clinically, patients develop progressive gait ataxia, dysarthria, sensory neuropathy, loss of deep tendon reflexes, scoliosis, and hypertrophic cardiomyopathy. Additional systemic manifestations such as diabetes may occur, while cognitive function is relatively preserved. Although most cases result from GAA expansions, FXN point mutations can also cause disease in compound-heterozygous states.

Epidemiologically, FRDA is more prevalent in populations of European ancestry but is observed globally across ethnic groups.

Key Highlights

• FRDA is a rare, progressive neuromuscular disorder with significant neurological and cardiac burden
• US prevalence is expected to increase from ~8.6K in 2025 to ~9.3K by 2035 (~0.7% CAGR)

Market Overview

• Germany market is projected to grow from ~$45M in 2025 to ~$135M by 2035 (~11-12% CAGR)
• Growth driven by emerging disease-modifying and gene-targeted therapies, with high unmet need in current care

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• PTC Therapeutics
• Design Therapeutics, Inc.
• Larimar Therapeutics, Inc.
• Biogen
• Lexeo Therapeutics
• Solid Biosciences Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)